Olaparib (AstraZeneca)will not proceed to Phase III in Ovarian Cancer - 20-Dec-2011

AstraZenenca announced that Olaparib will not progress into Phase III development for the maintenance treatment of serious Ovarian Cancer. The decision to discontinue olaparib’s development in Ovarian Cancer was made following a review of an interim analysis of a Phase II study (study 19) which indicated that the previously reported progression free survival benefit is unlikely to translate into an overall survival benefit, the definitive measure of patient benefit in Ovarian Cancer. In addition, attempts to identify a suitable tablet dose for use in Phase III studies have not been successful.

Related News

Phase II study of AZD6244 (AstraZeneca) shows benefits for patients with Ovarian Cancer

Phase III trial of MORAb 003 (Morphotek/Eisai) for Ovarian Cancer fails to meet primary endpoint

NICE does not recommend Avastin (Roche) as a treatment for Ovarian Cancer

CHMP recommends Avastin with chemotherapy and gemcitabine for Ovarian Cancer

Positive data from Phase III AURELIA trial of Avastin (Genentech/Roche) for Ovarian Cancer patients

Farletuzumab (Morphotek) now in Phase III trial for Ovarian Cancer

Olaparib (AstraZeneca)will not proceed to Phase III in Ovarian Cancer

FreeStyle InsuLinx Blood Glucose Monitoring System (Abbott) is recalled in the USA

Related Oncology Information

View all

Oncology Clinical Guidelines

Familial breast cancer: The classification and care of women at risk of familial breast cancer in primary, secondary and tertiary care

NICE

Prostate cancer: diagnosis and treatment

NICE
View all

Oncology Clinical Trials

Multi-Center Randomized Clinical Trial Irreversible Electroporation for the Ablation of Localized Prostate Cancer

Clinicaltrials.gov 08 April 2013

Pancreatic Carcinoma: Chemoradiation Compared With Chemotherapy Alone After Induction Chemotherapy (CONKO-007)

Clinicaltrials.gov 04 April 2013
View all

Oncology Medical Journal Abstracts

Bone mass density, fracture history, self-reported osteoporosis as proxy variables for estrogen and the risk of non-small-cell lung cancer—A population based cohort study, the HUNT study: Are proxy variables friends or faults?

Lung Cancer 24 April 2013

Prognostic value of K-RAS mutations in patients with non-small cell lung cancer: A systematic review with meta-analysis

Lung Cancer 22 April 2013
View all

Oncology Medical Apps

CCO Oncology inPractice

Free

Cancer Signs and Symptoms

Free

Related Oncology Drugs

Back to top
View all

Latest News

Takeda acquires vaccine maker Inviragen

10 May 2015

Takeda Pharmaceutical Company Limited and Inviragen, Inc. jointly announced that Takeda, its wholly owned subsidiary Takeda America...

Read full article

FreeStyle InsuLinx Blood Glucose Monitoring System (Abbott) is recalled in the USA

22 May 2013

The Freestyle Insulinx Blood Glucose Monitoring System has been recalled by Abbott Diabetes Care in the United States. The FDA has assigned...

Read full article

Genous stent (Orbus Neich) has lower restenosis rate than bare metal stents in ACS treatment

22 May 2013

OrbusNeich announced that the company's Genous Stent is associated with a significantly lower rate of binary restenosis compared to bare...

Read full article